Cantor Fitzgerald Comments on Heron Therapeutics, Inc.’s FY2017 Earnings (HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX) – Research analysts at Cantor Fitzgerald upped their FY2017 earnings per share (EPS) estimates for shares of Heron Therapeutics in a note issued to investors on Tuesday. Cantor Fitzgerald analyst L. Chen now forecasts that the biotechnology company will post earnings per share of ($3.45) for the year, up from their prior forecast of ($3.57). Cantor Fitzgerald has a “Buy” rating and a $31.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Heron Therapeutics’ FY2018 earnings at ($2.16) EPS.
Several other brokerages also recently weighed in on HRTX. Jefferies Group LLC reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. Northland Securities initiated coverage on Heron Therapeutics in a research note on Wednesday, September 27th. They set an “outperform” rating and a $40.00 target price on the stock. Noble Financial reaffirmed a “buy” rating and set a $24.00 target price on shares of Heron Therapeutics in a research note on Friday, October 6th. BidaskClub downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Finally, Zacks Investment Research raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Heron Therapeutics has an average rating of “Buy” and a consensus price target of $28.36.
TRADEMARK VIOLATION NOTICE: “Cantor Fitzgerald Comments on Heron Therapeutics, Inc.’s FY2017 Earnings (HRTX)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/cantor-fitzgerald-comments-on-heron-therapeutics-inc-s-fy2017-earnings-hrtx/1694698.html.
Heron Therapeutics (HRTX) opened at $16.35 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.72. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $20.85.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The business had revenue of $8.57 million during the quarter, compared to analyst estimates of $8.12 million.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN raised its stake in shares of Heron Therapeutics by 202.1% in the 3rd quarter. Wells Fargo & Company MN now owns 130,374 shares of the biotechnology company’s stock worth $2,106,000 after buying an additional 87,212 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Heron Therapeutics in the 3rd quarter worth $206,000. Chartwell Investment Partners LLC bought a new stake in shares of Heron Therapeutics in the 3rd quarter worth $2,340,000. C WorldWide Group Holding A S bought a new stake in shares of Heron Therapeutics in the 3rd quarter worth $1,615,000. Finally, Asymmetry Capital Management L.P. bought a new stake in shares of Heron Therapeutics in the 3rd quarter worth $1,017,000.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.